Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009;16(4):693-704.
doi: 10.3233/JAD-2009-1022.

Adiposity, type 2 diabetes, and Alzheimer's disease

José A Luchsinger  1 , Deborah R Gustafson
Affiliations
Review

Adiposity, type 2 diabetes, and Alzheimer's disease

José A Luchsinger et al. J Alzheimers Dis. 2009.

Abstract

This manuscript provides a comprehensive review of the epidemiologic evidence linking the continuum of adiposity and type 2 diabetes (T2D) with Alzheimer's disease (AD). The mechanisms relating adiposity and T2D to AD may include hyperinsulinemia, advanced products of glycosylation, cerebrovascular disease, and products of adipose tissue metabolism. Elevated adiposity in middle age is related to a higher risk of AD but the data on this association in old age is conflicting. Several studies have shown that hyperinsulinemia, a consequence of higher adiposity and insulin resistance, is also related to a higher risk of AD. Hyperinsulinemia is a risk factor for T2D, and numerous studies have shown a relation of T2D with higher AD risk. The implication of these associations is that a large proportion of the world population may be at increased risk of AD given the trends for increasing prevalence of overweight, obesity, hyperinsulinemia, and T2D. However these associations may present a unique opportunity for prevention and treatment of AD. Several studies in the prevention and treatment of T2D are currently conducting, or have planned, cognition ancillary studies. In addition, clinical trials using insulin sensitizers in the treatment or prevention of AD are under way.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr. Luchsinger has no conflicts of interest to report.

Dr. Gustafson has no conflicts of interest to report.

Figures

Figure 1
Figure 1
Mechanism linking the continuum of adiposity, insulin resistance and type 2 diabetes to the manifestation of Alzheimer's disease. Elevated adiposity leads to insulin resistance which precedes most cases of glucose intolerance and type 2 diabetes. Each of these conditions is related to specific mechanistic intermediaries, but most mechanisms are shared. For example, elevated adiposity, insulin resistance, and type 2 diabetes are all accompanied by hypertension and dyslipidemia. In addition, some of these mechanisms are bidirectional. For example, insulin resistance due to elevated adiposity results in increased inflammation which in turn increases insulin resistance. These mechanisms overlap and are highly correlated. In theory, these mechanistic intermediaries result in increased amyloid beta deposition and cerebrovascular disease. Cerebrovascular disease is thought to decrease the threshold at which amyloid deposition causes the manifestations of Alzheimer's disease, which starts with memory impairment, reaching the threshold of mild cognitive impairment, and eventually dementia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ritchie K, Lovestone S. The dementias. Lancet. 2002;360:1759–1766. - PubMed
    1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337–1342. - PMC - PubMed
    1. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989;262:2551–2556. - PubMed
    1. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997;275:630–631. - PubMed
    1. Cummings JL. Alzheimer's Disease. N Engl J Med. 2004;351:56–67. - PubMed

Publication types